<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_wGuBf7E">Pharmacist-Led Digital Health Interventions for Patients with Diabetes: A Systematic Review</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">© 2025 Christy et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution -Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).</p>
				</availability>
				<date type="published" when="2025-01-11">11 January 2025</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Alicia</forename><surname>Christy</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Pharmacology and Clinical Pharmacy , Universitas Padjadjaran , Sumedang Regency , Jatinangor , Indonesia;</note>
								<orgName type="department">Department of Pharmacology and Clinical Pharmacy</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<addrLine>Sumedang Regency</addrLine>
									<settlement>Jatinangor</settlement>
									<country>Indonesia;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frisca</forename><surname>Fernanda</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Pharmacology and Clinical Pharmacy , Universitas Padjadjaran , Sumedang Regency , Jatinangor , Indonesia;</note>
								<orgName type="department">Department of Pharmacology and Clinical Pharmacy</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<addrLine>Sumedang Regency</addrLine>
									<settlement>Jatinangor</settlement>
									<country>Indonesia;</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Widya</forename><forename type="middle">Norma</forename><surname>Insani</surname></persName>
							<email>widya.insani@unpad.ac.id</email>
							<idno type="ORCID">0000-0002-0066-9746</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Pharmacology and Clinical Pharmacy , Universitas Padjadjaran , Sumedang Regency , Jatinangor , Indonesia;</note>
								<orgName type="department">Department of Pharmacology and Clinical Pharmacy</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<addrLine>Sumedang Regency</addrLine>
									<settlement>Jatinangor</settlement>
									<country>Indonesia;</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Centre of Excellence for Pharmaceutical Care Innovation , Universitas Padjadjaran , Sumedang Regency , Jatinangor , Indonesia</note>
								<orgName type="department">Centre of Excellence for Pharmaceutical Care Innovation</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<addrLine>Sumedang Regency</addrLine>
									<settlement>Jatinangor</settlement>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rizky</forename><surname>Abdulah</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Pharmacology and Clinical Pharmacy , Universitas Padjadjaran , Sumedang Regency , Jatinangor , Indonesia;</note>
								<orgName type="department">Department of Pharmacology and Clinical Pharmacy</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<addrLine>Sumedang Regency</addrLine>
									<settlement>Jatinangor</settlement>
									<country>Indonesia;</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Centre of Excellence for Pharmaceutical Care Innovation , Universitas Padjadjaran , Sumedang Regency , Jatinangor , Indonesia</note>
								<orgName type="department">Centre of Excellence for Pharmaceutical Care Innovation</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<addrLine>Sumedang Regency</addrLine>
									<settlement>Jatinangor</settlement>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<note type="raw_affiliation">Department of Pharmacology and Clinical Pharmacy , Universitas Padjadjaran , Jl. Raya Bandung Sumedang KM 21 , Jatinangor , West Java , 45363 , Indonesia ,</note>
								<orgName type="department">Department of Pharmacology and Clinical Pharmacy</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<addrLine>Jl. Raya Bandung Sumedang KM 21 Jatinangor West Java</addrLine>
									<postCode>45363</postCode>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_UeqfcYg">Pharmacist-Led Digital Health Interventions for Patients with Diabetes: A Systematic Review</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2025-01-11">11 January 2025</date>
						</imprint>
					</monogr>
					<idno type="MD5">C406EB8ABCCC1FB91369096F948462B0</idno>
					<idno type="DOI">10.2147/jmdh.s494584</idno>
					<note type="submission">Received: 4 September 2024 Accepted: 26 November 2024</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T07:52+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_zmmNXgf">pharmacist</term>
					<term xml:id="_J5EpDP8">digital health intervention</term>
					<term xml:id="_YBwB2Sc">diabetes</term>
					<term xml:id="_HwCSvxe">clinical outcomes</term>
					<term xml:id="_5yXFrph">pharmaceutical care</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_88yzaBM"><p xml:id="_TSXJBxT"><s xml:id="_8zHZQTW">Digital health interventions have emerged as a promising approach for patient care.</s><s xml:id="_b6m8YQ7">The aim of this study was to conduct a systematic review of pharmacist-led digital health interventions for patients with diabetes.</s><s xml:id="_45Xd2jt">The PubMed database was used to select randomized controlled trials that assess the effectiveness of digital health interventions on clinical outcomes among patients with type 1 and 2 diabetes from January 2005 to May 2024.</s><s xml:id="_w2b5JJe">We included randomized controlled trial (RCT) studies on type 1 and 2 diabetes mellitus, analyzing the effects of all digital health interventions by pharmacists, including telephone-based intervention, web-based intervention, and mobile health application, as compared to usual care.</s><s xml:id="_kTdNwUk">The outcomes were a reduction in HbA1c, changes in medication adherence, and reduction of adverse effects.</s><s xml:id="_kb3Dt52">We used the PRISMA reporting standard to implement and report the results.</s><s xml:id="_SmB8865">A total of 19 studies were included.</s><s xml:id="_yNudx68">Among these, the included digital health interventions were telephone monitoring (n = 15), webbased intervention (n = 2), mobile health application (n = 1), and text-message reminder (n = 1).</s><s xml:id="_VXK2jd6">The findings showed variability: around half of the studies (n = 10, 52.63%) indicated that patients receiving digital health interventions had reduced HbA1c levels compared to those receiving usual care, while five studies (26.31%) found no difference between the intervention and usual care.</s><s xml:id="_mckVS5s">Five studies (26.31%) showed that such interventions increased medication adherence, while two studies (10.53%) found no difference when compared to standard care.</s><s xml:id="_r62wbsS">Effectiveness of the intervention is related to several factors, including practicability and patient engagement, frequency of the intervention, and the provision of personalized communication.</s><s xml:id="_TPqzqv2">Tailoring interventions to individual patient profiles and providing adequate support for enhancing practicability of these tools may improve their effectiveness.</s><s xml:id="_NJJtXR8">Further research assessing the cost-effectiveness of such intervention is necessary to inform healthcare policy.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_fWbcaqQ">Introduction</head><p xml:id="_A9BNnRt"><s xml:id="_hdNZBtU">Diabetes is a progressive and chronic metabolic disease, characterized by elevated blood glucose levels, which over time can result in organ damage and increase the risk of other metabolic conditions such as renal impairment, hypertension, and cardiovascular diseases. <ref type="bibr" target="#b0">1</ref></s><s xml:id="_bSgBAUD">Diabetes affects about 422 million people worldwide and is the cause of 1.5 million deaths each year, of which the majority are living in low-and middle-income countries. <ref type="bibr" target="#b1">2</ref></s><s xml:id="_PUFWQ7j">Pharmacotherapy is the cornerstone of diabetes treatment, involving antidiabetic agents such as insulin, sulfonylureas, and biguanides. <ref type="bibr" target="#b1">2</ref> Various factors may influence treatment outcomes among patients with diabetes, such as medication adherence, the presence of medicationrelated problems, and dietary compliance, which underscore the importance of personalized care and monitoring.</s><s xml:id="_nVH7Xrx">Previous study conducted regarding medication adherence of diabetic patients showed that about 50% of patients were non-adherent towards their prescribed antidiabetic medication. <ref type="bibr" target="#b2">3</ref></s><s xml:id="_TjsBmg9">harmacists play an important role in diabetes management, particularly through direct patient monitoring.</s><s xml:id="_nwDuS2S">Unlike other healthcare professionals, pharmacists have the advantage of more frequent patient interactions, as they do not require prior authorization for consultations. <ref type="bibr" target="#b3">4</ref></s><s xml:id="_y2KYHbx">Previous study showed that pharmaceutical care was associated with reductions in HbA1c (Hemoglobin A1c) by 1.24% in 2 years compared to the control group, which only reduced by -0.59%. <ref type="bibr" target="#b4">5</ref></s><s xml:id="_5jgZrQH">Orabone et al evaluated a pharmacist-managed diabetes program and found that pharmacist interventions in primary care resulted in reduced HbA1c and increased medication adherence. <ref type="bibr" target="#b5">6</ref></s><s xml:id="_2AfB6Et">igital health interventions (DHI) are defined as the use of digital and information technology to support and enhance health systems, patient care, and health outcomes. <ref type="bibr" target="#b6">7</ref></s><s xml:id="_CFMRnsS">The adoption of digital health intervention can further improve diabetes management by providing tools for continuous monitoring and personalized patient engagement.</s><s xml:id="_AVpkcNY">Pharmacist-led digital health intervention has some advantages including cost and resource efficiency.</s><s xml:id="_HUaKhq3">To our knowledge, no study has systematically reviewed the effectiveness of pharmacist-led digital health intervention for patients with diabetes.</s><s xml:id="_fgTkazs">Therefore, the objective of this review was to summarize the characteristics and effectiveness of pharmacist-led digital health intervention for people with diabetes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_JpwFyC7">Material and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RHccC8w">Search Strategy</head><p xml:id="_95RBXnE"><s xml:id="_PPpjzBx">The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used to guide the reporting of the findings.</s><s xml:id="_Yup9ss3">A systematic search was conducted within the PubMed database covering the period from January 2005 to May 2024.</s><s xml:id="_pBJNQZG">The search strategy included terms related to: i) digital health interventions; ii) pharmacist and pharmaceutical care; and iii) diabetes.</s><s xml:id="_GmCHuJn">The following keywords were used: ((Telepharmacy[tiab] OR automated medication system[tiab] OR electronic medication order entry[tiab] OR electronic medication management system [</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_hPwaQXD">Inclusion and Exclusion Criteria</head><p xml:id="_3KyJWRu"><s xml:id="_P6SUPnQ">We included randomized controlled trial (RCT) studies performed on adults with type 1 and 2 diabetes mellitus, assessing the impact of digital health interventions led by pharmacists.</s><s xml:id="_hNfbW9b">The outcomes were the reduction in HbA1c or fasting blood glucose (FBG), changes in medication adherence, fasting plasma glucose (FPG), two-hour postprandial glucose (2hPG) and reduction of adverse events, such as hypoglycemia.</s><s xml:id="_9heAAyP">Studies were excluded if they: (a) were not related to digital health interventions, (b) were not an RCT, (c) did not focus on diabetes mellitus, (d) were literature reviews/systematic reviews, RCT protocols, or conference abstracts, or (e) did not include a pharmacist in the intervention.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_CNtrWRT">Screening and Data Extraction</head><p xml:id="_UpuUpWA"><s xml:id="_M5Q2BKR">Two investigators (AC and FF) screened the titles and abstracts generated from the databases using the predetermined criteria.</s><s xml:id="_tKrXhbG">Any discrepancies between the two reviewers were then resolved through discussion with a third reviewer (WNI).</s><s xml:id="_udPmxFW">Following initial screening, the full text of potentially relevant papers were further assessed to identify eligible studies.</s><s xml:id="_2cNEJJs">The process of study selection was presented using an adapted PRISMA diagram.</s><s xml:id="_sVQ6ecg">The process of data extraction was conducted using a standardized data collection form for all included studies.</s><s xml:id="_TkemgAa">Data extracted included general characteristics of the studies, study design, and main findings.</s><s xml:id="_AaWNhAM">Journal of Multidisciplinary Healthcare 2025:18</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7QvPq8V">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_cDkG4Fw">Literature Search and Selection Process</head><p xml:id="_yas3hba"><s xml:id="_bQAZ6JW">Figure <ref type="figure">1</ref> presents a flowchart outlining the article selection process.</s><s xml:id="_6FD4b43">An initial database search yielded 49 articles from PubMed, from which titles and abstracts were screened.</s><s xml:id="_uTSxM8M">This initial screening led to the exclusion of 12 studies, resulting in 37 studies eligible for full-text review.</s><s xml:id="_fSDRZec">Following this second-level screening, 19 articles met the inclusion criteria and were incorporated into the final analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_f7mjXNX">Characteristics of the Studies</head><p xml:id="_hPSpQWJ"><s xml:id="_29jeEsD">Table <ref type="table" target="#tab_0">1</ref> shows a summary of all the results taken from 19 included studies.</s><s xml:id="_hnUvAs7">Half of the included studies were conducted in the United States of America (n = 10), <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref> and the rest were conducted in France (n = 2), <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b13">14</ref> China (n = 1), <ref type="bibr" target="#b10">11</ref> Thailand (n = 1), <ref type="bibr" target="#b11">12</ref> Iran (n = 1), <ref type="bibr" target="#b14">15</ref> Brazil (n = 1), <ref type="bibr" target="#b16">17</ref> England (n = 1), <ref type="bibr" target="#b20">21</ref> Malaysia (n = 1), <ref type="bibr" target="#b21">22</ref> and Jordan (n = 1). <ref type="bibr" target="#b22">23</ref> Sa</s><s xml:id="_uQ3fmDt">ple size of the studies ranged from 27 to 3734 patients.</s><s xml:id="_gpk8SaP">The types of digital interventions were telephone-based (n = 15), web-based (n = 2), mobilebased (n = 1), and text-message reminder (n = 1).</s><s xml:id="_ZfBJCmP">More than half of the studies assessed HbA1C (n =15) <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b25">26</ref> The remaining evaluated changes in medication adherence (n = 7).</s><s xml:id="_E8hEkkq"><ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b24">25</ref> Another study investigated the changes in FPG, 2hPG, and adverse event.</s><s xml:id="_YeNSv5J"><ref type="bibr" target="#b10">11</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_sTaN9Ae">Telephone-Based Intervention</head><p xml:id="_j8zb5Gm"><s xml:id="_McKHkms">We found that fifteen studies used telephone-based monitoring. <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref></s><s xml:id="_cAjWPjg">17]<ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref> Eight studies revealed the digital health interventions improved HbA1c level as compared to usual care <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b25">26</ref> and a total of five studies found no difference compared to the control group. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref></s><s xml:id="_9Za3TGR">9]<ref type="bibr" target="#b19">[20]</ref> Other than HbA1c, a total of five studies use telephone-based intervention to assess medication adherence.</s><s xml:id="_QbmwtCc">Three studies showed an increase in medication adherence, while two studies revealed no significant impact of digital health intervention on medication adherence (Table <ref type="table" target="#tab_2">2</ref>).</s><s xml:id="_GRYm3Rm">One study showed that with the help of DHIs, pharmacists could document more adverse events compared to usual care, showing that DHIs could as well help in the process of early detection of adverse events. <ref type="bibr" target="#b15">16</ref></s><s xml:id="_RpKkqU6">  104 privacy for patients.</s><s xml:id="_wZUtyz7">However, a drawback is the potential language barrier, as some studies only include one language, excluding patients who do not speak it.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dVq8qu4">Web-Based Intervention</head><p xml:id="_j7FARt6"><s xml:id="_9VTgSuA">Among the articles we studied, two studies used web-based interventions. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b21">22</ref></s><s xml:id="_Tnwv646">Web-based interventions can be described as a mostly self-guided program, executed by an online program operated through a website and used by consumers seeking health-related assistance. <ref type="bibr" target="#b26">27</ref></s><s xml:id="_EzdKzYJ">Usually, the intervention program itself attempts to create positive change and/or    <ref type="bibr" target="#b26">27</ref> This intervention enabled pharmacists to upload patient data, including blood glucose levels, which facilitated monitoring of disease progression and informed the selection of more effective treatment options. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b21">22</ref></s><s xml:id="_jNTbve7">Unfortunately, these two studies show that web-based interventions did not significantly lower the level of HbA1c compared to the control group.</s><s xml:id="_8ycxAht">The disadvantage of both studies is that patients did not directly use the web or software; instead, it was primarily operated by the pharmacist.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_n5bERRr">Mobile Health Application</head><p xml:id="_JCbMQNU"><s xml:id="_jdrM79q">One study used a mobile health application and another one used text message reminders. <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b13">14</ref></s><s xml:id="_rEmu9uQ">Patients used the mobile application to consult directly with the pharmacist, receive medication reminders, and access information about diabetes.</s></p><p xml:id="_BRBA9By"><s xml:id="_txsv9MH">The result was positive with a lower mean of HbA1c in the intervention group compared to the control group and higher medication adherence compared to the control group from baseline.</s><s xml:id="_SnZ5gMu">Mobile-based interventions have the advantage of supporting multiple languages, with the application translating according to the pharmacist's native language.</s><s xml:id="_QH5J8x5">However, the disadvantage is that patients need to know how to operate the application.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7HdfhZx">Text-Message Reminder</head><p xml:id="_fDHvMcM"><s xml:id="_XgymcwH">Text messages were used in one study. <ref type="bibr" target="#b13">14</ref></s><s xml:id="_a7xaWVV">In the article we reviewed, the text messages were sent automatically daily for three months in an SMS group and contained medication reminders sent every day and educational narrative content sent during the first 5 days of a week.</s><s xml:id="_NH2Sz4a">The narrative contents were divided into chapters, containing advice and important information relevant to type 2 diabetes, such as giving advice to increase physical activities, about food, lifestyle choices, etc.</s></p><p xml:id="_DrD9d4A"><s xml:id="_U23nNEZ">For the first day of the week, patients were sent a general fact, the next day they were sent a relevant information.</s><s xml:id="_ytntQTZ">The third day, patients were sent an open question, the fourth a tip, and the fifth a message designed to encourage them.</s><s xml:id="_gY63JKX">Patients were then subjected to follow ups through assessment after the first, second, and third months.</s><s xml:id="_xmUKCNc">During the third month's follow up, patient's satisfaction of the SMS service was evaluated.</s><s xml:id="_R2gexYf">For next three months, no text messages were sent, and assessments were then conducted again at the end of that point (6th month follow-up).</s><s xml:id="_aTrDyMy">Using daily reminder text messages also showed an improvement in patient medication adherence compared to usual care.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_PPwvXVU">Discussion</head><p xml:id="_HHXy5Zb"><s xml:id="_rRdFXR6">To our knowledge, this is the first systematic review to assess the effectiveness of pharmacist-led digital interventions for patients with type 1 and type 2 diabetes, assessing outcomes related to diabetes treatment, such as HbA1c and FBG, medication adherence, and reduction of adverse effects.</s><s xml:id="_MbP3H7F">Overall, the results were inconsistent.</s><s xml:id="_tQbWbaV">Around half of the studies (n = 9, 47.37%) showed that these interventions reduced HbA1c compared to usual care, while five studies (26.31%) showed there was no difference between the intervention and the control group. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref></s><s xml:id="_7zXxmXz">9]<ref type="bibr" target="#b19">[20]</ref> Four studies (21.05%) showed an increase in medication adherence compared to the control group, <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b24">25</ref> while two studies (10.53%) showed no difference compared to the control group. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b17">18</ref></s><s xml:id="_WmyCAX9">he effectiveness of the intervention is influenced by several factors, including its practicability and patient engagement, the frequency of intervention, the provision of personalized communication, and the integration with clinical care through automation.</s></p><p xml:id="_mM3DkHh"><s xml:id="_wTsQ8n6">We found that telephone-based monitoring was the most frequently used (n = 15, 78.95%) digital health intervention.</s><s xml:id="_JBAuRHr">Similarly, a previous systematic review evaluating the use of digital technology by community pharmacists to improve public health also found that telephone-based interventions were the most commonly used digital health intervention method compared to other strategies such as mobile application and web-based intervention. <ref type="bibr" target="#b27">28</ref></s><s xml:id="_QcHBaAx">We observed that telephone-based interventions showed superior efficacy in reducing HbA1c levels and increasing medication adherence compared to other forms of digital health interventions.</s><s xml:id="_g9VaCG8">Telephone-based interventions are relatively more straightforward, which might explain their effectiveness in this demographic.</s><s xml:id="_emWDdwb">For instance, a study focusing on digital health interventions for younger individuals (aged 16-35 years) found that web-based interventions, such as mental wellness websites, were more commonly utilized. <ref type="bibr" target="#b28">29</ref></s><s xml:id="_aVjvMUQ">This suggests that the simplicity of the intervention's approach may play a crucial role in its adoption and effectiveness, particularly among older patients with chronic diseases such as diabetes.</s></p><p xml:id="_YFkuuuu"><s xml:id="_jHWhYmY">In our review, several studies (n = 7, 36.84%)</s><s xml:id="_BUDeNh2">found no significant difference in diabetes outcomes between the digital health intervention and usual care.</s><s xml:id="_vqyujtq">The impersonal nature of these tools, ie, the lack of direct human interaction and personalized communication, which can add additional burden of care to both providers and patients, was cited as a barrier to the implementation of this intervention. <ref type="bibr" target="#b29">30</ref></s><s xml:id="_3HfugQr">In addition, access to digital technology, behavioral factors, and issues related with practicability of the intervention may also hinder the effectiveness. <ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b21">22</ref></s><s xml:id="_FB7EhdP">Future studies should consider these factors when designing interventions for patients with diabetes.</s></p><p xml:id="_bna9RYg"><s xml:id="_WbpWMhw">Another reason would be the frequencies of interventions.</s><s xml:id="_HY6bYwf">Three out of five studies utilizing telephone-based interventions that showed no significant difference had a frequency of phone calls ranging only from one to six.</s><s xml:id="_7Crv4KP">This suggests that a limited number of calls were insufficient to produce a meaningful impact on patient outcomes.</s><s xml:id="_ZvwJpcq">In a study by Lauffenburger et al, patients did not receive the necessary frequency of interventions.</s><s xml:id="_7jndefw">Of the 700 patients, only 202 responded to the first call, 106 (52.5%) continued to the second call, and only 52 (25.7%) received three or more calls.</s><s xml:id="_cSHsg35">This low frequency of interventions was likely insufficient, especially given the extended 12-month follow-up period. <ref type="bibr" target="#b17">18</ref></s><s xml:id="_D5d55Pw"> similar outcome was observed in one study, where no significant improvement in HbA1c levels was found.</s><s xml:id="_Zbsjd5j"><ref type="bibr" target="#b18">19</ref> Although the study used a phone call system, the calls had a median duration of less than 5 minutes, which appeared insufficient to yield significant results.</s></p><p xml:id="_n54FJuG"><s xml:id="_vHcgjFu">The follow-up period in the studies included in our review ranged from 3 to 24 months.</s><s xml:id="_BK6S5fe">Although 3 months is relatively short, this period was considered sufficient for evaluating HbA1c levels, as demonstrated in two studies. <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b12">13</ref></s><s xml:id="_jezvwRQ">This assessment is based on the average 3-month lifespan of red blood cells, allowing HbA1c levels to reflect any changes in lifestyle or medication adherence resulting from the intervention. <ref type="bibr" target="#b30">31</ref></s><s xml:id="_UYcjJFY">However, extended follow-up periods would offer a more comprehensive view of the long-term impact of digital interventions on medication adherence and disease management.</s><s xml:id="_abdAmsn">Prolonged intervention duration may also gradually influence patients' medication-taking behaviors. <ref type="bibr" target="#b31">32</ref></s><s xml:id="_ABDKvmJ"> study done by Schiff et al showed that patients in the intervention arm is more likely to have adverse effects.</s><s xml:id="_8KKfUzr">This could be caused by the fact that the DHI used in this study works as a media for patients to report adverse drug reactions and its severity.</s><s xml:id="_kkxKeR2">Therefore, the fact that patients in the intervention arm is found more likely to have adverse effects is favorable in terms of early detection of adverse events, and early detection leads to early management of adverse reactions.</s><s xml:id="_ve3Zetx">This makes it easier for medical practitioners including pharmacists to plan change of therapy regimen and education regarding hypoglycemia for diabetic patients, as awareness on symptoms of hypoglycemia is really important. <ref type="bibr" target="#b32">33</ref></s><s xml:id="_Wqk8BU6">n a study utilizing automated text-message reminders, the messages remained personalized by the pharmacist, tailored to each patient's profile with specific information on physical activity, diet, and daily lifestyle choices. <ref type="bibr" target="#b13">14</ref></s><s xml:id="_xs65fps">The automated text messaging yielded positive results, including a reduction in BMI and improved medication adherence; however, it did not lead to significant changes in HbA1c levels.</s><s xml:id="_BpPCyZY">A limitation of automated messaging is the absence of direct pharmacist interaction, which restricts opportunities for patient feedback and questions, thereby diminishing the pharmacist's supportive role.</s><s xml:id="_ZRJsPDT">Additionally, studies should explore integrating automated and semi-automated interventions to balance the time efficiency and personalized care provided by pharmacists.</s><s xml:id="_gFMfEyP">Although automated interventions like personalized text messaging showed promising results in improving medication adherence, the absence of direct pharmacist interaction may limit their overall impact.</s><s xml:id="_MvP87je">Hence, future studies should investigate hybrid approaches combining automated systems with opportunities for pharmacist feedback.</s><s xml:id="_tkkAg5q">For example, in the study done by Gillani et al, direct pharmacist intervention is still better than telemonitoring and usual care, proving the importance of direct pharmacist involvement. <ref type="bibr" target="#b21">22</ref></s><s xml:id="_5chY88R">igital health intervention could be used not only for disease monitoring but also to assist in the drug management process, eg, the clinical decision support system (CDSS) that provides medication safety alerts to reduce medication errors, such as dosing errors, contraindications, and drug-drug interactions in diabetes treatment. <ref type="bibr" target="#b33">34</ref></s><s xml:id="_f4QyB6v">As shown by the study done by Schiff et al, with the help of DHIs, pharmacists could document more adverse events compared to usual care, showing that DHIs could as well help in the process of early detection of adverse events. <ref type="bibr" target="#b15">16</ref></s><s xml:id="_DWqdbZ3">Nevertheless, this review indicates that there are still few studies addressing digital intervention for medication safety in diabetes.</s><s xml:id="_fHU34Mk">This review could serve as a foundation for further improving existing digital health interventions to enhance their effectiveness.</s></p><p xml:id="_EeDnuFD"><s xml:id="_fGB6xEc">Pharmacist-led digital interventions for other chronic diseases, such as hypertension, have shown that medication management through digital interventions improved blood pressure control. <ref type="bibr" target="#b32">33</ref></s><s xml:id="_TcA9EGq">Similar research conducted for patients with dyslipidemia demonstrated that a basic internet-based health management platform is moderately effective in controlling the patient's diet, physical activity, and tobacco use, thereby providing adequate protection against dyslipidemia. <ref type="bibr" target="#b34">35</ref></s><s xml:id="_PPGJVb2">These studies demonstrated that digital health interventions have the potential to improve disease control for chronic diseases.</s></p><p xml:id="_79JzsRT"><s xml:id="_VxBszs5">This study has several potential limitations.</s><s xml:id="_8VcVakR">First, only the PubMed database was used as a source for articles.</s><s xml:id="_XygdSUK">However, the decision to limit the search to PubMed was guided by the scope of our research.</s><s xml:id="_8595RBY">Our systematic review primarily focused on biomedical and clinical studies, for which PubMed serves as a highly comprehensive and widely recognized source.</s><s xml:id="_w8vh6gx">Second, although all the included studies employed RCTs, there remains a potential risk of selection <ref type="url" target="https://doi.org/10.2147/JMDH.S494584">https://doi.org/10.2147/JMDH.S494584</ref></s></p><p xml:id="_NR42znQ"><s xml:id="_trKzDHu">Journal of Multidisciplinary Healthcare 2025:18 bias, particularly in unblinded trials where restricted randomization is utilized to maintain equal group sizes. <ref type="bibr" target="#b35">36</ref></s><s xml:id="_AQvqtpE">eterogeneity in the types of interventions included in this review may limit the generalizability of the findings. <ref type="bibr" target="#b36">37</ref></s><s xml:id="_WarrXuC">The strengths of this review include its unique focus on pharmacist-led digital health interventions and its broad inclusion of various clinical outcomes, including HbA1c levels, medication adherence, and adverse effects.</s><s xml:id="_jMzXsCs">This approach provides a comprehensive understanding of the multifaceted impact of these interventions on patient health and supports evidencebased decision-making in digital health care.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_WhdmhQJ">Conclusion</head><p xml:id="_SZzqJFd"><s xml:id="_4ytv9S5">This review found that pharmacist-led digital health interventions for patients with diabetes included telephone-based monitoring, web-based intervention, mobile health application, and text-message reminder.</s><s xml:id="_GvdeXPN">The outcomes were inconclusive.</s><s xml:id="_eRxnRyN">While several studies demonstrated positive outcomes, such as reduced HbA1C levels and increased medication adherence, some research did not yield the anticipated results.</s><s xml:id="_QKFZjMg">The effectiveness of the intervention is influenced by several factors, including its practicability and patient engagement, the frequency of intervention, the provision of personalized communication.</s><s xml:id="_8zbgQZE">Further research assessing the cost-effectiveness of such intervention is necessary to inform healthcare policy.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><figDesc><div><p xml:id="_JRHaUTK"><s xml:id="_Z8VUPBd">tiab] OR automated dispensing[tiab] OR computerized reminder system[tiab] OR information technology[tiab] OR medication ordering entry-[tiab] OR electronic medication ordering and administration system[tiab] OR remote consultation[tiab] OR electronic consult*[tiab] OR digital technology*[tiab] OR teleconsult*[tiab] OR mhealth[tiab] OR m-health[tiab] OR multimedia[tiab] OR virtual[tiab] OR mobile health[tiab] OR telemedicine[tiab] OR electronic health record[tiab] OR telehealth[tiab] OR telecare[tiab] OR telehealth care[tiab] OR mobile health intervention*[tiab] OR mobile applications[tiab] OR mobile telemedicine[tiab] OR mcare[tiab] OR m-care[tiab] OR mobile communication[tiab] OR mobile technology*[tiab] OR multimedia technology*[tiab] OR mobile device*[tiab] OR app[tiab] OR apps[tiab] OR mobile app*[tiab] OR website* [tiab] OR internet consultation*[tiab] OR internet monitoring[tiab] OR video consultation*[tiab] OR video monitoring[tiab] OR telephone*[tiab] OR mobile phone*[tiab] OR smartphone*[tiab] OR smart-phone*[tiab] OR text message*[tiab] OR text messaging[tiab] OR SMS[tiab] OR short message*[tiab] OR multimedia message*[tiab] OR multi-media message*[tiab] OR website platform[tiab] OR web-based medication platform[tiab] OR web-based application[tiab] OR web-based tool[tiab] OR electronic health[tiab] OR ehealth[tiab] OR e-health[tiab])) AND (Pharmacist*[tiab] OR pharmaceutical care[tiab]) AND (diabetes[tiab]).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><figDesc><div><p xml:id="_CbcQ6JH"><s xml:id="_Wqg9W5E">https://doi.org/10.2147/JMDH.S494584 Journal of Multidisciplinary Healthcare 2025:18 102</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>37 )Figure 1</head><label>371</label><figDesc><div><p xml:id="_HQnUVHc"><s xml:id="_fSzVpQh">Figure 1 Flow Diagram of Systematic Review.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p xml:id="_gr3pwyD"><s xml:id="_VHpWegE">General Characteristics of Studies</s></p></div></figDesc><table><row><cell cols="2">No Author,</cell><cell>Setting</cell><cell cols="2">Country Subject</cell><cell>Design</cell><cell>Outcome</cell></row><row><cell></cell><cell>Publication</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Year</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Type 1 Diabetes Mellitus</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1.</cell><cell>Cohen et al,</cell><cell>1 medical center</cell><cell>United</cell><cell>Veterans with type 1 or type 2 diabetes with an</cell><cell>Open</cell><cell>Adherence</cell></row><row><cell></cell><cell>2019 8</cell><cell></cell><cell>States of</cell><cell>A1C 7.5% within the last six months, concomitant</cell><cell>label-RCT</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>America</cell><cell>depression as defined by International</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Classification of Diseases (ICD)-9 codes 311 or</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>296.2 to 296.3</cell><cell></cell><cell></cell></row><row><cell>2.</cell><cell>Gay et al,</cell><cell>1 clinic and 44</cell><cell>France</cell><cell>Type 1 diabetes patients for more than one year,</cell><cell>RCT</cell><cell>HbA1c</cell></row><row><cell></cell><cell>2006 9</cell><cell>pharmacies</cell><cell></cell><cell>aging 8-17 years old with HbA1c levels ≥8%</cell><cell></cell><cell></cell></row><row><cell cols="3">Type 2 Diabetes Mellitus</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1.</cell><cell>Gerber et al,</cell><cell>1 academic medical</cell><cell>United</cell><cell>Adult African American or Latinx patients (age</cell><cell>RCT</cell><cell>HbA1c</cell></row><row><cell></cell><cell>2023 10</cell><cell>center</cell><cell>States of</cell><cell>21-75) with type 2 diabetes and elevated HbA1c</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>America</cell><cell>(≥8%)</cell><cell></cell><cell></cell></row><row><cell>2.</cell><cell>Wang et al,</cell><cell>1 hospital</cell><cell>China</cell><cell>18-65 years of age, diagnosis of Type 2 Diabetes</cell><cell>RCT</cell><cell>Adherence,</cell></row><row><cell></cell><cell>2022 11</cell><cell></cell><cell></cell><cell>Mellitus (T2DM) and hypertension based on the</cell><cell></cell><cell>adverse event,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Chinese guidelines for the prevention and</cell><cell></cell><cell>FPG, 2hPG and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>treatment of type 2 diabetes mellitus (2017 edition)</cell><cell></cell><cell>HbA1c</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>and the Chinese guidelines for the management of</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>hypertension</cell><cell></cell><cell></cell></row><row><cell>3.</cell><cell>Poonprapai</cell><cell>1 hospital</cell><cell>Thailand</cell><cell>≥ 65 years of age, a diagnosis of type 2 diabetes,</cell><cell>RCT</cell><cell>Adherence and</cell></row><row><cell></cell><cell>et al, 2022 12</cell><cell></cell><cell></cell><cell>inadequate glycaemic control (glycosylated</cell><cell></cell><cell>HbA1c</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>hemoglobin (HbA1c) level &gt; 7% or 53 mmol/mol</cell><cell></cell><cell></cell></row><row><cell>4.</cell><cell>Peasah et al,</cell><cell>2 medical clinic</cell><cell>United</cell><cell>Patient aged 18 to 65 years old, taking at least 1</cell><cell>RCT</cell><cell>HbA1c</cell></row><row><cell></cell><cell>2019 13</cell><cell></cell><cell>States of</cell><cell>oral antidiabetic medication, and had an HbA1c of</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>America</cell><cell>7% within the last 12 months</cell><cell></cell><cell></cell></row><row><cell>5.</cell><cell>Gautier et al,</cell><cell>114 pharmacies</cell><cell>France</cell><cell>Patients were 18 years old with T2DM being</cell><cell>RCT</cell><cell>Adherence</cell></row><row><cell></cell><cell>2021 14</cell><cell></cell><cell></cell><cell>treated with at least one oral antidiabetic drug that</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>was delivered monthly</cell><cell></cell><cell></cell></row><row><cell>6.</cell><cell>Sarayani et al,</cell><cell>1 pharmacy</cell><cell>Iran</cell><cell>Patients over age 18 with type-2 diabetes</cell><cell>RCT</cell><cell>Adherence and</cell></row><row><cell></cell><cell>2018 15</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>HbA1c</cell></row><row><cell>7.</cell><cell>Schiff et al,</cell><cell>26 clinic</cell><cell>United</cell><cell>Patients over age 18 who received newly</cell><cell>Cluster</cell><cell>Adverse effects</cell></row><row><cell></cell><cell>2019 16</cell><cell></cell><cell>States of</cell><cell>prescribed medication for diabetes</cell><cell>RCT</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>America</cell><cell></cell><cell></cell><cell></cell></row><row><cell>8.</cell><cell>Aguiar et al,</cell><cell>1 care clinic</cell><cell>Brazil</cell><cell>Patients with type 2 diabetes, aged 40-79 years and</cell><cell>RCT</cell><cell>HbA1c</cell></row><row><cell></cell><cell>2018 17</cell><cell></cell><cell></cell><cell>glycosylated haemoglobin (A1C) level ≥ 7.0%.</cell><cell></cell><cell></cell></row><row><cell>9.</cell><cell>Lauffenburger</cell><cell>1 health insurer</cell><cell>United</cell><cell>Patients ≥18 years of age who filled 1 or more oral</cell><cell>Pragmatic</cell><cell>Adherence and</cell></row><row><cell></cell><cell>et al, 2019 18</cell><cell></cell><cell>States of</cell><cell>hypoglycemic agents within the 12 months prior to</cell><cell>RCT</cell><cell>HbA1c</cell></row><row><cell></cell><cell></cell><cell></cell><cell>America</cell><cell>randomization and who had evidence of poor</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>diabetic control (HbA1c ≥8%)</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(Continued)</cell></row></table><note xml:id="_YhUJg7Z"><p><s xml:id="_JgQahmx">https://doi.org/10.2147/JMDH.S494584 Journal of Multidisciplinary Healthcare 2025:18</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 (</head><label>1</label><figDesc><div><p xml:id="_xjJ7jm8"><s xml:id="_f6Z7wYd">Continued).</s></p></div></figDesc><table><row><cell cols="2">No Author,</cell><cell>Setting</cell><cell cols="2">Country Subject</cell><cell>Design</cell><cell>Outcome</cell></row><row><cell></cell><cell>Publication</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Year</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>10.</cell><cell>O'Connor</cell><cell>1 integrated care</cell><cell>United</cell><cell>Diabetes patients aged 18-75 who received clinical</cell><cell>Cluster</cell><cell>HbA1c</cell></row><row><cell></cell><cell>et al, 2014 19</cell><cell>consortium, 1</cell><cell>States of</cell><cell>care at designated clinic or medical center involved</cell><cell>RCT</cell><cell></cell></row><row><cell></cell><cell></cell><cell>insurance agency, and</cell><cell>America</cell><cell>in this study for at least 15 months before study</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>2 clinics</cell><cell></cell><cell>enrollment, and were prescribed a new class of</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>medication for A1C, blood pressure (BP), or low</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>density lipoprotein (LDL) cholesterol uncontrolled</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>at the time of medication prescription (A1C ≥8%,</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>systolic BP [SBP] ≥140 mmHg, or LDL cholesterol</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>≥100 mg/dL).</cell><cell></cell><cell></cell></row><row><cell>11.</cell><cell>Odegard et al,</cell><cell>1 clinic</cell><cell>United</cell><cell>All adult patients with type 2 diabetes, taking at</cell><cell>RCT</cell><cell>HbA1c</cell></row><row><cell></cell><cell>2005 20</cell><cell></cell><cell>States of</cell><cell>least one oral diabetes medication, with HbA1c</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>America</cell><cell>≥9%</cell><cell></cell><cell></cell></row><row><cell>12.</cell><cell>Lyons et al,</cell><cell>Patients recruited</cell><cell>England</cell><cell>Patients aged &gt; 18 prescribed at least one oral</cell><cell>RCT</cell><cell>HbA1c</cell></row><row><cell></cell><cell>2015 21</cell><cell>through an internet</cell><cell></cell><cell>medication for type 2 diabetes and/or lipid</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>and mail-order</cell><cell></cell><cell>regulation were recruited through 'Pharmacy2U',</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>pharmacy</cell><cell></cell><cell>a UK National Health Service (NHS)-contracted</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>internet and mail-order pharmacy</cell><cell></cell><cell></cell></row><row><cell>13.</cell><cell>Wasif Gillani,</cell><cell>Diabetic clinics and</cell><cell>Malaysia</cell><cell>Patients with type 2 diabetes diagnosed by</cell><cell>RCT</cell><cell>HbA1c</cell></row><row><cell></cell><cell>2016 22</cell><cell>hospital</cell><cell></cell><cell>a physician at least six months before the study,</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>aging 18-75 years old, with HbA1c ≥7.5% but less</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>than 11%</cell><cell></cell><cell></cell></row><row><cell>14.</cell><cell>Jarab et al,</cell><cell>1 hospital</cell><cell>Jordan</cell><cell>Type 2 diabetes patients diagnosed at least 1 year</cell><cell>RCT</cell><cell>HbA1c</cell></row><row><cell></cell><cell>2012 23</cell><cell></cell><cell></cell><cell>prior to the study aged ≥ 18 years old, who took at</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>least 1 prescribed medication for diabetes, and</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>HbA1c levels ≥7.5%</cell><cell></cell><cell></cell></row><row><cell>15.</cell><cell>Choe et al,</cell><cell>1 university-affiliated</cell><cell>United</cell><cell>Type 2 adult diabetes patients not older than 70</cell><cell>RCT</cell><cell>HbA1c</cell></row><row><cell></cell><cell>2005 24</cell><cell>primary care</cell><cell>States of</cell><cell>years old with recent HbA1c levels ≥8%</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>America</cell><cell></cell><cell></cell><cell></cell></row><row><cell>16.</cell><cell>Odegard and</cell><cell>4 Pharmacies</cell><cell>United</cell><cell>Patients with type 2 diabetes aging &gt;18 years old</cell><cell>RCT</cell><cell>Adherence</cell></row><row><cell></cell><cell>Christensen,</cell><cell></cell><cell>States of</cell><cell>and are using at least one oral prescription diabetes</cell><cell></cell><cell></cell></row><row><cell></cell><cell>2012 25</cell><cell></cell><cell>America</cell><cell>medication, which are overdue for prescription</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>refills by 6 days or more</cell><cell></cell><cell></cell></row><row><cell>17.</cell><cell>Lauffenburger</cell><cell>1 health insurer</cell><cell>United</cell><cell>Patients 18 years or older with type 2 diabetes, in</cell><cell>3 armed</cell><cell>HbA1c</cell></row><row><cell></cell><cell>et al, 2019 26</cell><cell></cell><cell>States of</cell><cell>claims or previous fills of an oral hypoglycemic</cell><cell>pragmatic</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>America</cell><cell>medication, who filled 1 or more basal (long-acting)</cell><cell>RCT</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>insulin prescriptions in the 6 months before</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>random-ization</cell><cell></cell><cell></cell></row><row><cell cols="3">Journal of Multidisciplinary Healthcare 2025:18</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc><div><p xml:id="_zpWzJpm"><s xml:id="_Y98s6n2">Main Findings of the Studies</s></p></div></figDesc><table><row><cell cols="2">No Author,</cell><cell>Intervention (n, Mean Age, %</cell><cell>Control (n, Mean</cell><cell>Follow-Up</cell><cell>Main Findings</cell></row><row><cell></cell><cell>Publication</cell><cell>Female, Frequencies)</cell><cell>Age, % Female)</cell><cell>Period</cell><cell></cell></row><row><cell></cell><cell>Year</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Type 1 Diabetes Mellitus</cell><cell></cell><cell></cell><cell></cell></row><row><cell>1.</cell><cell>Cohen et al,</cell><cell>Telepharmacy (phone calls,</cell><cell>Usual care/ nurse-led</cell><cell>6 months</cell><cell>No significant raise in diabetes</cell></row><row><cell></cell><cell>2019 8</cell><cell>medication review) for counseling (n</cell><cell>telehealth (n = 14,</cell><cell></cell><cell>medication adherence (mean of</cell></row><row><cell></cell><cell></cell><cell>= 13, 63.1 ± 12.2, 0%, twice in 6</cell><cell>60.5 ± 9.4, 86.7%)</cell><cell></cell><cell>3.9%) compared to control patients</cell></row><row><cell></cell><cell></cell><cell>months for phone calls, everyday for</cell><cell></cell><cell></cell><cell>(mean of 2.6%)</cell></row><row><cell></cell><cell></cell><cell>medication reminder)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>2.</cell><cell>Gay et al,</cell><cell>Telemonitoring through a software</cell><cell>Usual care (n = 50,</cell><cell>6 months</cell><cell>No significant difference in HbA1c</cell></row><row><cell></cell><cell>2006 9</cell><cell>capable to download, analyze, and</cell><cell>13.5 ± 2.5, 36%)</cell><cell></cell><cell>decrease found between children in</cell></row><row><cell></cell><cell></cell><cell>print blood glucose monitoring data</cell><cell></cell><cell></cell><cell>the intervention (-0,10 ± 1.10) and</cell></row><row><cell></cell><cell></cell><cell>(n = 50, 13.2 ± 2.7, 42%, every</cell><cell></cell><cell></cell><cell>control group (0.10 ± 1.05)</cell></row><row><cell></cell><cell></cell><cell>2 weeks)</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Type 2 Diabetes Mellitus</cell><cell></cell><cell></cell><cell></cell></row><row><cell>1.</cell><cell>Gerber et al,</cell><cell>Telepharmacy (phone calls, remote</cell><cell>Usual care (n = 112,</cell><cell>24 months</cell><cell>Lower mean HbA1c -0.79% in</cell></row><row><cell></cell><cell>2023 10</cell><cell>support) for counseling (n = 109,</cell><cell>54.5 ± 9.6, 68.8%)</cell><cell></cell><cell>interventions patients compared to</cell></row><row><cell></cell><cell></cell><cell>56.0 ± 9.3, 70.6%, every 2-3 months)</cell><cell></cell><cell></cell><cell>-0.24% in control patients</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(P &lt; 0.005)</cell></row><row><cell>2.</cell><cell>Wang et al,</cell><cell>Telepharmacy (phone calls) for</cell><cell>Usual care (n = 40, 43,</cell><cell>3 months</cell><cell>Increased in medication adherence</cell></row><row><cell></cell><cell>2022 11</cell><cell>medication education, medication</cell><cell>40%)</cell><cell></cell><cell>90% in interventions patients and</cell></row><row><cell></cell><cell></cell><cell>taking reminder and counseling (n =</cell><cell></cell><cell></cell><cell>52.5% in control patients (P &lt; 0.001)</cell></row><row><cell></cell><cell></cell><cell>40, 42, 42.5%, every 2 weeks)</cell><cell></cell><cell></cell><cell>Significant differences in HbA1c 6.5%</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>in interventions patients and 7.0% in</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>control patients (P = 0.007)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Differences in FPG 6.50 in</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>interventions patients and 7.00 in</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>control patients (P = 0.004)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Differences in 2hPG 8.45 in</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>interventions patients and 9.35 in</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>control patients (P = 0.007)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Five recorded adverse event in control</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>patients (hypoglycemic [n = 2], rash</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>[n = 2], and nausea [n = 1]) and zero in</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>interventions patients</cell></row><row><cell>3.</cell><cell>Poonprapai</cell><cell>Mobile-based intervention (provided</cell><cell>Usual care (n = 79,</cell><cell>9 months</cell><cell>Lower mean HbA1c -0.97% in</cell></row><row><cell></cell><cell>et al, 2022 12</cell><cell>information, medication reminder,</cell><cell>67.80 ± 6.18, 59.5%)</cell><cell></cell><cell>interventions patients compared to</cell></row><row><cell></cell><cell></cell><cell>and counseling using mobile apps) (n</cell><cell></cell><cell></cell><cell>-0.12% in control patients</cell></row><row><cell></cell><cell></cell><cell>= 78, 67.36 ± 5.72, 60.3%, daily for 3</cell><cell></cell><cell></cell><cell>(P = 0.001)</cell></row><row><cell></cell><cell></cell><cell>months for diabetes education, 4 times/day for medication reminder)</cell><cell></cell><cell></cell><cell>Increased medication adherence 1.61 ± 3.4 in intervention group</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>compared to 0.94 ± 1.71 in control</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>group</cell></row><row><cell>4.</cell><cell>Peasah et al,</cell><cell>Telepharmacy (phone calls) for</cell><cell>Usual care (n = 39,</cell><cell>3 months</cell><cell>Lower mean HbA1c -0.35% in</cell></row><row><cell></cell><cell>2019 13</cell><cell>medication refill reminder,</cell><cell>59.0 ± 10.0, 41%)</cell><cell></cell><cell>interventions patients and increased</cell></row><row><cell></cell><cell></cell><cell>medication reminder, and counseling</cell><cell></cell><cell></cell><cell>mean HbA1c 0.338% in control</cell></row><row><cell></cell><cell></cell><cell>(n = 39, 64.3 ± 10.7, 54%, weekly)</cell><cell></cell><cell></cell><cell>patients</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(Continued)</cell></row></table><note xml:id="_7Y85Ggd"><p><s xml:id="_KAgZjJ3">https://doi.org/10.2147/JMDH.S494584 Journal of Multidisciplinary Healthcare 2025:18</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 (</head><label>2</label><figDesc><div><p xml:id="_fAh5RsQ"><s xml:id="_eGNKqQU">Continued).</s></p></div></figDesc><table><row><cell cols="2">No Author,</cell><cell>Intervention (n, Mean Age, %</cell><cell>Control (n, Mean</cell><cell>Follow-Up</cell><cell>Main Findings</cell></row><row><cell></cell><cell>Publication</cell><cell>Female, Frequencies)</cell><cell>Age, % Female)</cell><cell>Period</cell><cell></cell></row><row><cell></cell><cell>Year</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>5.</cell><cell>Gautier et al,</cell><cell>Telepharmacy (text message) for</cell><cell>Usual care (n = 140,</cell><cell>3 months</cell><cell>Increased medication adherence 0.58</cell></row><row><cell></cell><cell>2021 14</cell><cell>medication taking reminder, lifestyle</cell><cell>64.8 ± 9.9, 36.5%)</cell><cell></cell><cell>±1.29 in interventions patients and</cell></row><row><cell></cell><cell></cell><cell>advices, and follow-up medical</cell><cell></cell><cell></cell><cell>0.12±1.27 in control patients (P =</cell></row><row><cell></cell><cell></cell><cell>appointments (n = 156, 60.2 ± 10.6,</cell><cell></cell><cell></cell><cell>0.004)</cell></row><row><cell></cell><cell></cell><cell>47.1%, daily)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>6.</cell><cell>Sarayani et al,</cell><cell>Telepharmacy (phone calls) for</cell><cell>Usual care (n = 44,</cell><cell>9 months</cell><cell>Decreased mean HbA1c 0.81±1.12 in</cell></row><row><cell></cell><cell>2018 15</cell><cell>counseling drug therapy problem and</cell><cell>56.7 ± 11.5, 38%)</cell><cell></cell><cell>interventions patients and 1.03±1.41</cell></row><row><cell></cell><cell></cell><cell>blood glucose level (n = 40, 53.4 ±</cell><cell></cell><cell></cell><cell>in control patients.</cell></row><row><cell></cell><cell></cell><cell>10.3, 45.1%, 16 calls in 3 months)</cell><cell></cell><cell></cell><cell>Increased medication adherence with</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>high level of adherence patients 63%</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>in interventions patients and 22.9% in</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>control patients</cell></row><row><cell>7.</cell><cell>Schiff et al,</cell><cell>Telepharmacy (phone calls) for</cell><cell>Usual care (n = 776,</cell><cell>4 months</cell><cell>Intervention patients were</cell></row><row><cell></cell><cell>2019 16</cell><cell>counseling of new symptom including</cell><cell>59.7, 74.9%)</cell><cell></cell><cell>significantly more likely to have</cell></row><row><cell></cell><cell></cell><cell>the severity level (n = 776, 57.2,</cell><cell></cell><cell></cell><cell>adverse effects (277 vs 164 adverse</cell></row><row><cell></cell><cell></cell><cell>66.6%, 10 calls in two weeks)</cell><cell></cell><cell></cell><cell>effects, p &lt; 0.0001, and 177 vs 122</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>patients discontinued with</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>documented adverse effects, p &lt;</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.0001)</cell></row><row><cell>8.</cell><cell>Aguiar et al,</cell><cell>Telepharmacy (phone calls) and</cell><cell>Usual care (n = 37,</cell><cell>12 months</cell><cell>Lower mean HbA1c -0.79% in</cell></row><row><cell></cell><cell>2018 17</cell><cell>medication chart (n = 36, 61.1 ± 7.9,</cell><cell>62.4 ± 8.2, 64.9%)</cell><cell></cell><cell>interventions patients compared to</cell></row><row><cell></cell><cell></cell><cell>69.4%, 1-2 calls between 2-6</cell><cell></cell><cell></cell><cell>-0.16% in control patients (P =</cell></row><row><cell></cell><cell></cell><cell>months)</cell><cell></cell><cell></cell><cell>0.010)</cell></row><row><cell>9.</cell><cell>Lauffenburger</cell><cell>Telepharmacy (phone calls) for</cell><cell>Usual care (n = 678,</cell><cell>12 months</cell><cell>No improvement in HbA1c in</cell></row><row><cell></cell><cell>et al, 2019 18</cell><cell>medication reviewing and giving</cell><cell>54.9 ± 8.1, 34.6%)</cell><cell></cell><cell>patients subjected to intervention</cell></row><row><cell></cell><cell></cell><cell>suggestion to improve the patients</cell><cell></cell><cell></cell><cell>(mean change = -0.75±1.96) with</cell></row><row><cell></cell><cell></cell><cell>diabetes control (n = 684, 54.6 ± 8.4,</cell><cell></cell><cell></cell><cell>usual care (mean change = -0.79</cell></row><row><cell></cell><cell></cell><cell>39.8%, 1-6 calls)</cell><cell></cell><cell></cell><cell>±2.01) and no improvement in</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>adherence either.</cell></row><row><cell>10.</cell><cell>O'Connor</cell><cell>Electronic medical records (EMRs),</cell><cell>Usual care (n = 1158,</cell><cell>2 months and</cell><cell>No significant decrease of HbA1c in</cell></row><row><cell></cell><cell>et al, 2014 19</cell><cell>Telepharmacy (phone calls) for</cell><cell>62.04 ± 13.37, 53.1%)</cell><cell>6 months</cell><cell>patients in the intervention arm</cell></row><row><cell></cell><cell></cell><cell>counseling (n = 1220, 61.67 ± 13.03,</cell><cell></cell><cell></cell><cell>(change from baseline -1,08%)</cell></row><row><cell></cell><cell></cell><cell>51.1%, 1 call)</cell><cell></cell><cell></cell><cell>compared to patients in control arm</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(change from baseline -0,90%)</cell></row><row><cell>11.</cell><cell>Odegard et al,</cell><cell>Electronic notation in medical</cell><cell>Usual care (n = 34,</cell><cell>6 months</cell><cell>No significant reduction in HbA1c</cell></row><row><cell></cell><cell>2005 20</cell><cell>records and weekly telephone</cell><cell>51.9 ± 10.4, 38%)</cell><cell></cell><cell>levels in intervention arm compared</cell></row><row><cell></cell><cell></cell><cell>meetings (n = 43, 51.6 ±11.6, 48%,</cell><cell></cell><cell></cell><cell>to control arm</cell></row><row><cell></cell><cell></cell><cell>weekly)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>12.</cell><cell>Lyons et al,</cell><cell>Telephone consultations and</cell><cell>Usual care (n = 337,</cell><cell>6 months</cell><cell>Intervention group has twice the</cell></row><row><cell></cell><cell>2015 21</cell><cell>a medicine reminder chart (n = 340,</cell><cell>69.9 ± 10.1, 43.9%)</cell><cell></cell><cell>proportion of participants achieving</cell></row><row><cell></cell><cell></cell><cell>69.9 ± 9.2, 39.1%, 2 calls 4-6 weeks</cell><cell></cell><cell></cell><cell>HbA1c level of 7% (66.7%, n=16)</cell></row><row><cell></cell><cell></cell><cell>apart)</cell><cell></cell><cell></cell><cell>compared with the control group</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(31.3%, n=5)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(Continued)</cell></row></table><note xml:id="_gae3exF"><p><s xml:id="_Vejtx46">Journal of Multidisciplinary Healthcare 2025:18 https://doi.org/10.2147/JMDH.S494584 107 improve patient's knowledge, awareness, and understanding by providing good health-related material and use of interactive Web-based components.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2 (</head><label>2</label><figDesc><div><p xml:id="_f25v3Hm"><s xml:id="_X9bjXAb">Continued).</s></p></div></figDesc><table><row><cell cols="2">No Author,</cell><cell>Intervention (n, Mean Age, %</cell><cell>Control (n, Mean</cell><cell>Follow-Up</cell><cell>Main Findings</cell></row><row><cell></cell><cell>Publication</cell><cell>Female, Frequencies)</cell><cell>Age, % Female)</cell><cell>Period</cell><cell></cell></row><row><cell></cell><cell>Year</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>13.</cell><cell>Wasif Gillani,</cell><cell>Telemonitoring through a web-</cell><cell>Usual care (n = 50, 54</cell><cell>6 months</cell><cell>Direct pharmacist intervention is</cell></row><row><cell></cell><cell>2016 22</cell><cell>enabled glucometer connected to an</cell><cell>± 10.29, 42%), and</cell><cell></cell><cell>better than the telemonitoring and</cell></row><row><cell></cell><cell></cell><cell>online portal (n = 50, 53 ± 10.19,</cell><cell>Pharmacist</cell><cell></cell><cell>control arm in improving patient's</cell></row><row><cell></cell><cell></cell><cell>46%, daily)</cell><cell>Intervention (n = 50,</cell><cell></cell><cell>clinical outcomes</cell></row><row><cell></cell><cell></cell><cell></cell><cell>52 ± 9.81, 42%)</cell><cell></cell><cell></cell></row><row><cell>14.</cell><cell>Jarab et al,</cell><cell>Telepharmacy (phone calls) to review</cell><cell>Usual care (n = 79,</cell><cell>6 months</cell><cell>A significant mean decrease in</cell></row><row><cell></cell><cell>2012 23</cell><cell>the prescribed medication and</cell><cell>65.3 ± 9.2, 44.2%)</cell><cell></cell><cell>HbA1c was noticed in the</cell></row><row><cell></cell><cell></cell><cell>answering patient questions (n = 77,</cell><cell></cell><cell></cell><cell>intervention arm (0,8%) compared to</cell></row><row><cell></cell><cell></cell><cell>63.4 ± 10.1, 42.4%, weekly for</cell><cell></cell><cell></cell><cell>the control arm (0,1%)</cell></row><row><cell></cell><cell></cell><cell>8 weeks)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>15.</cell><cell>Choe et al,</cell><cell>Telepharmacy (phone calls) for</cell><cell>Usual care (n = 29, 51</cell><cell>12 months</cell><cell>Intervention group has more of</cell></row><row><cell></cell><cell>2005 24</cell><cell>counseling (n = 36, 52.2 ± 11.2,</cell><cell>± 9.0, 53.9%)</cell><cell></cell><cell>a significant decrease in HbA1c levels</cell></row><row><cell></cell><cell></cell><cell>51.2%, 1 per month)</cell><cell></cell><cell></cell><cell>(mean decrease = 2.1 ± 2.5)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>compared to the control group</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(mean decrease = 0.9 ± 2.0)</cell></row><row><cell>16.</cell><cell>Odegard and</cell><cell>Telepharmacy (phone calls) for</cell><cell>Usual care (n = 145,</cell><cell>12 months</cell><cell>At 12 months, MPR (Medication</cell></row><row><cell></cell><cell>Christensen,</cell><cell>counseling (n = 120, 65 ± 13, 53.8%,</cell><cell>61 ± 13, 50.3%)</cell><cell></cell><cell>possession ratio) was significantly</cell></row><row><cell></cell><cell>2012 25</cell><cell>calls initiated for missed refills)</cell><cell></cell><cell></cell><cell>improved for the study group</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>compared with the control group</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(difference between groups, P =</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.01). Intervention showed greater</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>effect for patients with baseline MPR</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>less than 80%. Likelihood of MPR</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>above 80% at the 12 month follow-</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>up for any patient significantly</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>favored the intervention group</cell></row><row><cell>17.</cell><cell>Lauffenburger</cell><cell>Telepharmacy (phone calls) for</cell><cell>Untargeted low</cell><cell>12 months</cell><cell>Glycemic control was similar in arm</cell></row><row><cell></cell><cell>et al, 2019 26</cell><cell>counseling with different intervention</cell><cell>intensity care (n =</cell><cell></cell><cell>2 and arm 1 (absolute HbA1c level</cell></row><row><cell></cell><cell></cell><cell>intensity between the three arms.</cell><cell>1861, 55.9 ± 11.0,</cell><cell></cell><cell>difference, -0.15%; 95% Confidence</cell></row><row><cell></cell><cell></cell><cell>(1st arm = untargeted low intensity,</cell><cell>39.7%)</cell><cell></cell><cell>Interval (CI), -0.34% to 0.05%) but</cell></row><row><cell></cell><cell></cell><cell>2nd arm = partially targeted</cell><cell></cell><cell></cell><cell>was better in arm 3 (absolute HbA1c</cell></row><row><cell></cell><cell></cell><cell>moderate intensity, 3rd arm = highly</cell><cell></cell><cell></cell><cell>level difference, -0.25%; 95% CI, -</cell></row><row><cell></cell><cell></cell><cell>targeted high intensity) (n 2nd arm =</cell><cell></cell><cell></cell><cell>0.43% to -0.06%)</cell></row><row><cell></cell><cell></cell><cell>1873, 55.4 ± 11.3, 39.3%; n 3rd arm</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>= 1862, 55.9 ± 1.7, 40.7%,1st arm = 2</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>follow-up calls, 2nd arm = 6 follow-</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>up calls, 3rd arm = 12 follow-up calls)</cell><cell></cell><cell></cell><cell></cell></row></table><note xml:id="_WKxwXjj"><p><s xml:id="_bmDsWnN">https://doi.org/10.2147/JMDH.S494584 Journal of Multidisciplinary Healthcare 2025:18 108</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_rJASMs5"><s xml:id="_xtgwbRy">Powered by TCPDF (www.tcpdf.org)</s><s xml:id="_4k4vNA2">Powered by TCPDF (www.tcpdf.org)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_PyskyWb"><s xml:id="_WPuk36d">Journal of Multidisciplinary Healthcare 2025:18 https://doi.org/10.2147/JMDH.S494584</s></p></note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_svj7mkr">Abbreviations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_cSrb3x3">Disclosure</head><p xml:id="_wskBHa5"><s xml:id="_uEDG9Bh">The authors report no conflicts of interest in this work.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_6xZQus8">Pathophysiology of diabetes: an overview</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Z</forename><surname>Banday</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Sameer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nissar</surname></persName>
		</author>
		<idno type="DOI">10.4103/ajm.ajm_53_20</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DkpnXtQ">Avicenna J Med</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">04</biblScope>
			<biblScope unit="page" from="174" to="188" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: an overview. Avicenna J Med. 2020;10(04):174-188. doi:10.4103/ajm.ajm_53_20</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<idno type="DOI">10.2471/b09146</idno>
		<ptr target="https://www.who.int/health-topics/diabetes" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_TEDvnt2">Diabetes</title>
		<imprint>
			<date type="published" when="2024-07-01">2024. July 1, 2024</date>
			<publisher>World Health Organization</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">World Health Organization. Diabetes, 2024, Accessed July 1, 2024. Available from: https://www.who.int/health-topics/diabetes.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_u9BMb8Z">Factors related to barriers and medication adherence in patients with type 2 diabetes mellitus: a cross-sectional study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Zairina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Nugraheni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sulistyarini</surname></persName>
		</author>
		<idno type="DOI">10.1007/s40200-021-00961-6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EJu4TYK">J Diabetes Metab Disord</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="219" to="228" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zairina E, Nugraheni G, Sulistyarini A, et al. Factors related to barriers and medication adherence in patients with type 2 diabetes mellitus: a cross-sectional study. J Diabetes Metab Disord. 2022;21(1):219-228. doi:10.1007/s40200-021-00961-6</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_eJ6uWE3">Pharmacists as accessible primary health care providers: review of the evidence</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Tsuyuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Beahm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Okada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Al</forename><surname>Hamarneh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">N</forename></persName>
		</author>
		<idno type="DOI">10.1177/1715163517745517</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jw3gyPa">Canad Pharm J</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="4" to="5" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tsuyuki RT, Beahm NP, Okada H, Al Hamarneh YN. Pharmacists as accessible primary health care providers: review of the evidence. Canad Pharm J. 2018;151(1):4-5. doi:10.1177/1715163517745517</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_QCTz72r">Analysis of Glycemic Control of a Pharmacist-Led Medication Management Program in Patients with Type 2 Diabetes</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rascati</surname></persName>
		</author>
		<idno type="DOI">10.18553/jmcp.2016.22.1.32</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hZYDGgS">J Manag Care Spec Pharm</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="32" to="37" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ko JJ, Lu J, Rascati K, et al. Analysis of Glycemic Control of a Pharmacist-Led Medication Management Program in Patients with Type 2 Diabetes. J Manag Care Spec Pharm. 2016;22(1):32-37. doi:10.18553/jmcp.2016.22.1.32</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_nPgA6jj">Pharmacist-Managed Diabetes Programs: improving Treatment Adherence and Patient Outcomes</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Orabone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Do</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cohen</surname></persName>
		</author>
		<idno type="DOI">10.2147/dmso.s342936</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Sxm4ahw">Diabetes Metab Syndr Obes</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="1911" to="1923" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Orabone AW, Do V, Cohen E. Pharmacist-Managed Diabetes Programs: improving Treatment Adherence and Patient Outcomes. Diabetes Metab Syndr Obes. 2022;20(15):1911-1923. doi:10.2147/DMSO.S342936</note>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main" xml:id="_cVRFgWK">Recommendations on digital interventions for health system strengthening</title>
		<idno type="DOI">10.1016/j.vaccine.2017.07.046</idno>
		<ptr target="https://www.who.int/publications/i/item/9789241550505" />
		<imprint>
			<date type="published" when="2019-07-01">2019. July 1, 2024</date>
			<publisher>World Health Organization</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">World Health Organization. Recommendations on digital interventions for health system strengthening; 2019. Accessed July 1, 2024. Available from: https://www.who.int/publications/i/item/9789241550505.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_xcDv5P8">Pharmacist-led telehealth disease management program for patients with diabetes and depression</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Taveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Pirraglia</surname></persName>
		</author>
		<idno type="DOI">10.1177/1357633x18822575</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_z7xSB6U">J Telemed Telecare</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="294" to="302" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cohen LB, Taveira TH, Wu WC, Pirraglia PA. Pharmacist-led telehealth disease management program for patients with diabetes and depression. J Telemed Telecare. 2020;26(5):294-302. doi:10.1177/1357633X18822575</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_2hcTcr4">Reinforced follow-up for children and adolescents with type 1 diabetes and inadequate glycaemic control: a randomized controlled trial intervention via the local pharmacist and telecare</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Gay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chapuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bendelac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tixier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Treppoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nicolino</surname></persName>
		</author>
		<idno type="DOI">10.1016/s1262-3636(07)70263-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YfXMTzh">Diabetes Metab</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="159" to="165" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gay CL, Chapuis F, Bendelac N, Tixier F, Treppoz S, Nicolino M. Reinforced follow-up for children and adolescents with type 1 diabetes and inadequate glycaemic control: a randomized controlled trial intervention via the local pharmacist and telecare. Diabetes Metab. 2006;32 (2):159-165. doi:10.1016/S1262-3636(07)70263-X</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_RaKXbf9">Mobile Health Intervention in Patients With Type 2 Diabetes: a Randomized Clinical Trial</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Gerber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Biggers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Tilton</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamanetworkopen.2023.33629</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aWxwhFG">JAMA Netw Open</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">2333629</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gerber BS, Biggers A, Tilton JJ, et al. Mobile Health Intervention in Patients With Type 2 Diabetes: a Randomized Clinical Trial. JAMA Netw Open. 2023;6(9):e2333629. doi:10.1001/jamanetworkopen.2023.33629</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_3YqgKBD">Efficacy of Pharmaceutical Care in Patients with Type 2 Diabetes Mellitus and Hypertension: a Randomized Controlled Trial</title>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Geng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1155/2022/7681404</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NUwFjPg">Int J Clin Pract</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page">7681404</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang W, Geng L, Sun C, Li H, Wang J. Efficacy of Pharmaceutical Care in Patients with Type 2 Diabetes Mellitus and Hypertension: a Randomized Controlled Trial. Int J Clin Pract. 2022;24:7681404.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_4N4aFwc">Family support-based intervention using a mobile application provided by pharmacists for older adults with diabetes to improve glycaemic control: a randomised controlled trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Poonprapai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lerkiatbundit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Saengcharoen</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11096-022-01389-5</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vKPZZW3">Int J Clin Pharm</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="680" to="688" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Poonprapai P, Lerkiatbundit S, Saengcharoen W. Family support-based intervention using a mobile application provided by pharmacists for older adults with diabetes to improve glycaemic control: a randomised controlled trial. Int J Clin Pharm. 2022;44(3):680-688. doi:10.1007/s11096-022- 01389-5</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_dNAERrz">Effectiveness of a Student Pharmacist-Led Telephone Follow-Up Intervention to Improve Hemoglobin A1C in Diabetic Patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Peasah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Granitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jacob</surname></persName>
		</author>
		<idno type="DOI">10.1177/0897190019857409</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KN8m5VM">J Pharm Pract</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="832" to="837" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Peasah SK, Granitz K, Vu M, Jacob B. Effectiveness of a Student Pharmacist-Led Telephone Follow-Up Intervention to Improve Hemoglobin A1C in Diabetic Patients. J Pharm Pract. 2020;33(6):832-837. doi:10.1177/0897190019857409</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_K23s35U">Impact of personalized text messages from pharmacists on medication adherence in type 2 diabetes in France: a real-world, randomized, comparative study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Gautier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Boitard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Michiels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Raymond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vergez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Guedon</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.pec.2021.02.022</idno>
		<ptr target="https://doi.org/10.2147/JMDH.S494584" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_8mJDKub">Patient Educ Couns</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2250" to="2258" />
			<date type="published" when="2021">2021. 2025</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gautier JF, Boitard C, Michiels Y, Raymond G, Vergez G, Guedon G. Impact of personalized text messages from pharmacists on medication adherence in type 2 diabetes in France: a real-world, randomized, comparative study. Patient Educ Couns. 2021;104(9):2250-2258. doi:10.1016/j. pec.2021.02.022 Journal of Multidisciplinary Healthcare 2025:18 https://doi.org/10.2147/JMDH.S494584</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_vP46PPM">Efficacy of a telephone-based intervention among patients with type-2 diabetes; a randomized controlled trial in pharmacy practice</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sarayani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mashayekhi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nosrati</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11096-018-0593-0</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pzxE3fd">Int J Clin Pharm</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="345" to="353" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sarayani A, Mashayekhi M, Nosrati M, et al. Efficacy of a telephone-based intervention among patients with type-2 diabetes; a randomized controlled trial in pharmacy practice. Int J Clin Pharm. 2018;40(2):345-353. doi:10.1007/s11096-018-0593-0</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_w3g8QTR">Screening for Adverse Drug Events: a Randomized Trial of Automated Calls Coupled with Phone-Based Pharmacist Counseling</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Schiff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Klinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Salazar</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11606-018-4672-7</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Q9cPZKF">J Gen Intern Med</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="285" to="292" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schiff GD, Klinger E, Salazar A, et al. Screening for Adverse Drug Events: a Randomized Trial of Automated Calls Coupled with Phone-Based Pharmacist Counseling. J Gen Intern Med. 2019;34(2):285-292. doi:10.1007/s11606-018-4672-7</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_p2nPYc5">Pharmacist-physician collaborative care model for patients with uncontrolled type 2 diabetes in Brazil: results from a randomized controlled trial</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Aguiar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chp</forename><surname>Da Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chiann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Dórea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Lj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Storpirtis</surname></persName>
		</author>
		<idno type="DOI">10.1111/jep.12606</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_x5HxuGU">J Eval Clin Pract</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="22" to="30" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aguiar PM, da Silva CHP, Chiann C, Dórea EL, DP LJ, Storpirtis S. Pharmacist-physician collaborative care model for patients with uncontrolled type 2 diabetes in Brazil: results from a randomized controlled trial. J Eval Clin Pract. 2018;24(1):22-30. doi:10.1111/jep.12606</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_gDwf2Ev">Impact of a novel pharmacist-delivered behavioral intervention for patients with poorly-controlled diabetes: the ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) pragmatic randomized trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lauffenburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ghazinouri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jan</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0214754</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_k2P95Wr">PLoS One</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">214754</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lauffenburger JC, Ghazinouri R, Jan S, et al. Impact of a novel pharmacist-delivered behavioral intervention for patients with poorly-controlled diabetes: the ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) pragmatic randomized trial. PLoS One. 2019;14(4):e0214754. doi:10.1371/journal.pone.0214754</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_wPS6bu2">Randomized trial of telephone outreach to improve medication adherence and metabolic control in adults with diabetes</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>O'connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Schmittdiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Pathak</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc14-0596</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_p2AAQCs">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3317" to="3324" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">O&apos;Connor PJ, Schmittdiel JA, Pathak RD, et al. Randomized trial of telephone outreach to improve medication adherence and metabolic control in adults with diabetes. Diabetes Care. 2014;37(12):3317-3324. doi:10.2337/dc14-0596</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_FGyErQA">Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Odegard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Goo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Gray</surname></persName>
		</author>
		<idno type="DOI">10.1345/aph.1e438</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7hK989n">Ann Pharmacother</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="433" to="440" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Odegard PS, Goo A, Hummel J, Williams KL, Gray SL. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother. 2005;39(3):433-440. doi:10.1345/aph.1E438</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_5ttum4Z">The Medicines Advice Service Evaluation (MASE): a randomised controlled trial of a pharmacist-led telephone based intervention designed to improve medication adherence</title>
		<author>
			<persName><forename type="first">I</forename><surname>Lyons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Barber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Raynor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wei</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjqs-2015-004670</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KgcvFnF">BMJ Qual Saf</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="759" to="769" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lyons I, Barber N, Raynor DK, Wei L. The Medicines Advice Service Evaluation (MASE): a randomised controlled trial of a pharmacist-led telephone based intervention designed to improve medication adherence. BMJ Qual Saf. 2016;25(10):759-769. doi:10.1136/bmjqs-2015-004670</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_jeVUFTG">Determining Effective Diabetic Care; A Multicentre -Longitudinal Interventional Study</title>
		<author>
			<persName><forename type="first">Wasif</forename><surname>Gillani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<idno type="DOI">10.2174/1381612822666160813235704</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TD7Jc4d">Curr Pharm Des</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">42</biblScope>
			<biblScope unit="page" from="6469" to="6476" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wasif Gillani S. Determining Effective Diabetic Care; A Multicentre -Longitudinal Interventional Study. Curr Pharm Des. 2016;22 (42):6469-6476. doi:10.2174/1381612822666160813235704</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_MJFzkAB">Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Jarab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Alqudah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Mukattash</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Shattat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Al-Qirim</surname></persName>
		</author>
		<idno type="DOI">10.18553/jmcp.2012.18.7.516</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Kjzt7D8">J Manag Care Pharm</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="516" to="526" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. J Manag Care Pharm. 2012;18(7):516-526. doi:10.18553/jmcp.2012.18.7.516</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_mP3dJvJ">Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Choe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mitrovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dubay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Hayward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Krein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vijan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5NGvsEv">Am J Manag Care</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="253" to="260" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11(4):253-260.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_g3MBxcG">MAP study: RCT of a medication adherence program for patients with type 2 diabetes</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Odegard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Christensen</surname></persName>
		</author>
		<idno type="DOI">10.1331/japha.2012.11001</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_a2X4cqp">J Am Pharm Assoc</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="753" to="762" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Odegard PS, Christensen DB. MAP study: RCT of a medication adherence program for patients with type 2 diabetes. J Am Pharm Assoc. 2012;52 (6):753-762. doi:10.1331/JAPhA.2012.11001</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_paer4Tb">Effectiveness of Targeted Insulin-Adherence Interventions for Glycemic Control Using Predictive Analytics Among Patients With Type 2 Diabetes: a Randomized Clinical Trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lauffenburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lewey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jan</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.1001/jamanetworkopen.2019.0657</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_m73Vu5C">JAMA Netw Open</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">190657</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lauffenburger JC, Lewey J, Jan S, et al. Effectiveness of Targeted Insulin-Adherence Interventions for Glycemic Control Using Predictive Analytics Among Patients With Type 2 Diabetes: a Randomized Clinical Trial. JAMA Netw Open. 2019;2(3):e190657. doi:10.1001/jamanetworkopen.2019.0657</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_tcuUvgP">Web-based interventions for behavior change and self-management: potential, pitfalls, and progress</title>
		<author>
			<persName><forename type="first">E</forename><surname>Murray</surname></persName>
		</author>
		<idno type="DOI">10.2196/med20.1741</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Q3BC3ax">Med</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">0</biblScope>
			<biblScope unit="page">3</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Murray E. Web-based interventions for behavior change and self-management: potential, pitfalls, and progress. Med 2 0. 2012;1(2):e3. doi:10.2196/ med20.1741</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_HGaGuDH">A Systematic Review of Randomized Controlled Trials of Telehealth and Digital Technology Use by Community Pharmacists to Improve Public Health</title>
		<author>
			<persName><forename type="first">P</forename><surname>Crilly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kayyali</surname></persName>
		</author>
		<idno type="DOI">10.3390/pharmacy8030137</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zcuxPT4">Pharmacy</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">137</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Crilly P, Kayyali R. A Systematic Review of Randomized Controlled Trials of Telehealth and Digital Technology Use by Community Pharmacists to Improve Public Health. Pharmacy. 2020;8(3):137. doi:10.3390/pharmacy8030137</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_56pFtEm">Co-design of Digital Health Interventions for Young Adults: protocol for a Scoping Review</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Malloy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Partridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kemper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Braakhuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Roy</surname></persName>
		</author>
		<idno type="DOI">10.2196/38635</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Zaj8tXU">JMIR Res Protoc</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">38635</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Malloy JA, Partridge SR, Kemper JA, Braakhuis A, Roy R. Co-design of Digital Health Interventions for Young Adults: protocol for a Scoping Review. JMIR Res Protoc. 2022;11(10):e38635. doi:10.2196/38635</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_YhVdDqU">Barriers and facilitators to the implementation of digital technologies in mental health systems: a qualitative systematic review to inform a policy framework</title>
		<author>
			<persName><forename type="first">C</forename><surname>Berardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Antonini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wechtler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Paolucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hinwood</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12913-023-10536-1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fMF9hPy">BMC Health Serv Res</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">243</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Berardi C, Antonini M, Jordan Z, Wechtler H, Paolucci F, Hinwood M. Barriers and facilitators to the implementation of digital technologies in mental health systems: a qualitative systematic review to inform a policy framework. BMC Health Serv Res. 2024;24(1):243. doi:10.1186/s12913- 023-10536-1</note>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m" type="main" xml:id="_3M45dup">Hemoglobin A1C</title>
		<author>
			<persName><forename type="first">E</forename><surname>Eyth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Naik</surname></persName>
		</author>
		<ptr target="https://www.ncbi.nlm.nih.gov/books/NBK549816/" />
		<imprint>
			<date type="published" when="2024-01-01">2024. Jan 1, 2025</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Eyth E, Naik R. Hemoglobin A1C; 2024. Accessed Jan 1, 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549816/.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_RzzGmCf">Effects of weight loss with diet and/or exercise on abdominal adipose tissue distribution: a 12-month randomized intervention trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Apolzan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Bray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pBWsjgW">PLoS One</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">1</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Apolzan JW, Bray GA, Smith SR, et al. Effects of weight loss with diet and/or exercise on abdominal adipose tissue distribution: a 12-month randomized intervention trial. PLoS One. 2019;14(3):1.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_UgtdgZY">Effectiveness of Internet-based health management in patients with dyslipidemia: a four-year longitudinal study</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Dou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ma</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.atherosclerosis.2023.04.004</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fvwUUg4">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="page" from="34" to="42" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dou Y, Chen B, Yu X, Ma D. Effectiveness of Internet-based health management in patients with dyslipidemia: a four-year longitudinal study. Atherosclerosis. 2023;376:34-42. doi:10.1016/j.atherosclerosis.2023.04.004</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_aMZRU4X">Applications of Clinical Decision Support Systems in Diabetes Care: scoping Review</title>
		<author>
			<persName><forename type="first">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.2196/51024</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6ncr82P">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">51024</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Huang S, Liang Y, Li J, Li X. Applications of Clinical Decision Support Systems in Diabetes Care: scoping Review. J Med Internet Res. 2023;25: e51024. doi:10.2196/51024</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_TsVzT4k">Evaluation of pharmacist-led telemedicine medication management for hypertension established patients during COVID-19 pandemic: a pilot study</title>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yao</surname></persName>
		</author>
		<idno type="DOI">10.3389/fpubh.2022.1091484</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_X6frKfG">Front Public Health</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">1091484</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li X, Hu J, Yao Y, et al. Evaluation of pharmacist-led telemedicine medication management for hypertension established patients during COVID-19 pandemic: a pilot study. Front Public Health. 2022;10:1091484. doi:10.3389/fpubh.2022.1091484</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_u6P2PHR">Risk of selection bias in randomised trials</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Kahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rehal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cro</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13063-015-0920-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fE5UAef">Trials</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">405</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kahan BC, Rehal S, Cro S. Risk of selection bias in randomised trials. Trials. 2015;16(1):405. doi:10.1186/s13063-015-0920-x</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_WCsc2hp">Empirical evidence about inconsistency among studies in a pair-wise meta-analysis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Rhodes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<idno type="DOI">10.1002/jrsm.1193</idno>
		<ptr target="https://www.dovepress.com/journal-of-multidisciplinary-healthcare" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_JJv5TjP">Journal of Multidisciplinary Healthcare</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">18</biblScope>
			<date type="published" when="2016">2016. 2025</date>
		</imprint>
	</monogr>
	<note>of Multidisciplinary Healthcare Publish your work in this journal The Journal of Multidisciplinary Healthcare is an international, peer-reviewed open-access journal that aims to represent and publish research in healthcare areas delivered by practitioners of different disciplines. This includes studies and reviews conducted by multidisciplinary teams as well as research which evaluates the results or conduct of such teams or healthcare processes in general. The journal covers a very wide range of areas and welcomes submissions from practitioners at all levels, from all over the world. The manuscript management system is completely online and includes a very quick and fair peer-review system to read real quotes from published authors. Submit your manuscript here Res Synth Methods</note>
	<note type="raw_reference">Rhodes KM, Turner RM, Higgins JP. Empirical evidence about inconsistency among studies in a pair-wise meta-analysis. Res Synth Methods. 2016;7(4):346-370. doi:10.1002/jrsm.1193 Journal of Multidisciplinary Healthcare Publish your work in this journal The Journal of Multidisciplinary Healthcare is an international, peer-reviewed open-access journal that aims to represent and publish research in healthcare areas delivered by practitioners of different disciplines. This includes studies and reviews conducted by multidisciplinary teams as well as research which evaluates the results or conduct of such teams or healthcare processes in general. The journal covers a very wide range of areas and welcomes submissions from practitioners at all levels, from all over the world. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors. Submit your manuscript here: https://www.dovepress.com/journal-of-multidisciplinary-healthcare-journal Journal of Multidisciplinary Healthcare 2025:18</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
